Per Wold-Olsen

Mr. Wold-Olsen joined Gilead's Board of Directors in January 2010 after serving as the Chair of the company's Health Policy Advisory Board since 2007. He retired from Merck & Co, Inc., where he was President of the Human Health Intercontinental Division from 2005 to 2006 and President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing from 1995 to 2005. In his more than 30-year career at Merck, Mr. Wold-Olsen held various leadership positions within the company with responsibility for 15,000 employees in more than 100 markets in Europe, Eastern Europe, Middle East/Africa, India, Latin America and Canada.

Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S and Chairman of the Board of Oncopeptides AB. He is also the Chair of the Board of the Medicines for Malaria Venture (MMV), a nonprofit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria. Mr. Wold-Olsen previously served as a director of Novo A/S, PharmaNet Development Group, Inc., Royal Dutch Numico, Exicon A/S and H. Lundbeck A/S.

Mr. Wold-Olsen received MBAs in Economics/Administration from the Norwegian School of Management and in Management/Marketing from the University of Wisconsin.